This is a snippet of the transcript, sign up to read more.
I normally like to remind myself of the history, so let's go over Sectra's competition narrative. Sectra has been a pioneer since the 1990s. Philips was a major distributor for Sectra on the license side until 2005, before they bought a competitor in the US, thinking Sectra would go bankrupt. However, Sectra ended up taking two-thirds of all the end customers in the US and other places, which fueled significant growth from 2005 onward.
This is a snippet of the transcript, sign up to read more.
The transition to a RIS software, a radar information system, similar to an ERP for invoicing, also contributed to this growth. Today, it's essentially one system. The competition evolved from there, and Sectra became even stronger. In 2011, we sold the modality business in mammography to focus solely on software, moving away from hardware. From a financial and investment perspective, the transition to the cloud began around 2011. By 2015 or 2016, the push towards the cloud was very strong.
This is a snippet of the transcript, sign up to read more.
Culturally, and because Sectra has won that class for more than 10 years in a row. The big hospitals and production hospitals have that background. They have Kaiser Permanente and Stanford as references, which Visage doesn't have.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research